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 Abstract 
The accumulation and infiltration of eosinophils in airways is one of the most 
important characteristics of asthma, and is mediated partly by secretion of IL-5 from 
Th2 lymphocytes. It is well known that interleukin-5 (IL-5) played an important role 
in the regulation of eosinophils. In this study, an anti-sense IL-5 gene transferred by 
recombinant adeno-associated virus (rAAV-ASIL-5) was prepared to transfect allergic 
rats. It was found that the expression of IL-5 protein in plasma and BALF were 
inhibited significantly. The rAAV-ASIL-5-mediated suppression of total cell counts in 
peripheral blood and BALF were also observed. Moreover, rAAV-ASIL-5 remarkably 
reduced the eosinophil counts in peripheral blood and BALF, as well as the 
expression of ECP protein in plasma and BALF. The inflammation in lungs of 
rAAV-ASIL-5 pretreated rats also became slighter when compared with allergic rats. 
Otherwise, no apparent pathological damage to vital organs of rats was found. In 
conclusion, recombinant adeno-associated virus-mediated delivery of anti-sense IL-5 
gene inhibited the accumulation of eosinophils and the airways inflammation in rat 
model of allergic asthma via suppressing IL-5 expression. It suggested the feasibility 
of rAAV-ASIL-5 in the gene therapy for allergic asthma and other eosinophilic 
diseases. 
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 Introduction 
Asthma is a complex chronic inflammation disease of airways which is 
characterized by reversible airway obstruction, bronchial hyper-reactivity and airway 
inflammation with eosinophils, mast cells and T lymphocytes infiltration (1). 
Eosinophil is thought to be major effecter cell in the inflammation process of asthma. 
The accumulation and infiltration of airways eosinophils is one of the most important 
characteristics of asthma (2). There is a strong association between airways 
eosinophils inflammation and the development of lung pathology in asthma. Activated 
eosinophils can release oxygen free radicals and toxic granule proteins, such as 
eosinophil cationic protein (ECP), major basic protein (MBP), eosinophil protein 
X/eosinophil derived neurotoxin (EPX/EDN) and eosinophil peroxidase (EPO). ECP 
and MBP are highly cationic proteins with a number of biological activities of which 
the cytotoxic potency of the protein is more conspicuous. They may be assayed in 
most biological fluids as markers of eosinophil activity and turnover. EPO produces 
hypophalous acid capable of killing parasites by oxidizing halides (3). In addition, 
activated eosinophils can also generate membrane derived lipid mediators, for 
instance platelet-activating factor (PAF) and leukotriene-C4 (LTC4), as well as 
reactive oxygen species that may add to their proinflammatory effects (4, 5). 
Eosinophils inflammation is considered as one of the most important contributors to 
the structural and functional changes in airways of asthma, including bronchial 
hyper-reactivity, damage to epithelial cells, hyperplasia of goblet cells, hypertrophy of 
the airway smooth muscle cells and fibrosis (6, 7). The presence of eosinophils and 
their products in airways are recognized contributors to the disease severity and the 
development of airway hyper-reactivity in asthma (3, 8). 
Interleukin-5 (IL-5) is mainly produced by activated Th2 cells, a sort of CD4+ T 
lymphocytes. It has been long established that IL-5 is vital in promoting eosinophils 
proliferation, differentiation and survival (9). Previous researches revealed that IL-5 is 
one of the most critical regulatory factors of eosinophils (10, 11). IL-5 play an 
important role in activating eosinophils, preventing eosinophils apoptosis, inducing 
eosinophils precursor cells differentiation, and encouraging toxic granule proteins and 
 inflammation mediators secreting from eosinophils (12, 13). Furthermore, IL-5 has 
the functions of gathering eosinophils, reinforcing antigen-inducing eosinophils 
degranulation reaction, and enhancing antibody-dependent cytotoxic effect (14). 
Therefore, as a sort of representative cytokine produced from overplenty Th2 cells in 
asthma, IL-5 may act a vital role in the development of asthma. The suppression of 
IL-5 is theoretically beneficial to therapy for asthma. 
Preceding researches revealed that anti-IL-5 therapy could suppress the airway 
inflammation and hyper-reactivity in asthmatic mice. Eosinophils and airways 
hyper-reactivity to inhaled methacholine did not develop in OVA sensitized and 
challenged IL-5-deficient BALB/c mice (15). An anti-sense oligonucleotide of IL-5 
significantly inhibited eosinophils in vivo, coincided with specifically reduce of IL-5 
protein level in both the murine OVA challenged and allergic peritonitis models (16). 
The treatment of anti-IL-5 antibody also had remarkable anti-inflammation effects on 
OVA sensitized and challenged BALB/c mice, including decreasing the numbers of 
both intraepithelial eosinophils and chronic inflammatory cells in the airway wall, 
inhibiting the development of subepithelial fibrosis et al (17). Many clinic studies 
(18-20) also manifested that anti-IL-5 therapy inhibited the expression of IL-5 and 
prevented eosinophils accumulation in vivo.  
Although the therapy of asthma with anti-IL-5 monoclonal antibody is beneficial 
and feasible, there are still some questions which restricted the widely application of 
anti-IL-5 monoclonal antibody, such as the problems of immunity reaction and 
persistent effect. Moreover, anti-IL-5 monoclonal antibody only inhibited IL-5 protein 
which had been excreted, but not fundamentally reduced the potential synthesis of 
IL-5. New methods should be investigated for a more stable and long-term treating 
effect on the development of asthma. 
Following with the rapid development of molecular biology, we could integrate the 
objective gene in chromatosome via the technology of gene interfere, for instance the 
virus vector mediated delivery. Several viral vectors, including lentivirus, adenovirus, 
rAAV and other viral vectors can be adaptive for gene therapy of genetic or chronic 
diseases. The rAAV vector, which either integrates into the genome or remains in the 
 nucleus as a stable episome, offers attractive advantages and may be one of the most 
promising gene vector for long-term therapy (21). The AAV has many advantages and 
properties compared with other vectors, such as the lack of inflammatory response, 
the ability to infect the dividing and non-dividing cells, especially including T 
lymphocytes (22, 23). The AAV is safe to use because of not producing viral proteins 
that stimulate inflammatory reactions and not replicating inside cells without the 
presence of a wild-type adenovirus (24, 25). The AAV is effective as a vector as it 
contains sufficient carrying capacity for the insertion of many sorts of exogenous 
genes. As a result, it is possible for exogenous gene to produce a sustained and 
marked effect through persistent expression (26, 27). In this way, finding a long-term 
treatment method could become easier. 
In our past research (28), we found that a rAAV-ASIL-5 suppressed the expression 
of IL-5 mRNA and protein in CD4+ T lymphocytes of allergic asthmatic rat model in 
vitro. On this base, aiming to observe the effect of rAAV-ASIL-5 on allergic rat in 
vivo, we constructed a kind of novel rAAV vector which may mediate a persistent 
anti-sense IL-5 gene expression, and then transfected allergic rats with it through tail 
vein. 
 
 
 
 
 
 
 
 
 
 
 
 
 Materials and Methods 
Construction of plasmid pSNAV-ASIL-5 and pSNAV-EGFP 
Vector plasmid pSNAV (29) was bought from Vector Gene Technology Co. Ltd. 
(China). The genome of plasmid pSNAV contained inverted terminal repeats (ITR) of 
rAAV and cytomegalovirus immediate early (CMV IE) promoter followed by a 
multiple clone site (MCS). The MCS included several sites of restriction enzyme, 
such as NotI and EcoRV et al. A plasmid pASIL-5 which containing the anti-sense 
IL-5 gene was constructed previously (28). Fragment which contained the complete 
cDNA of rat IL-5 gene was obtained from the plasmid pASIL-5. Then it was inserted 
into the pSNAV-X vector in the anti-sense orientation between the restriction enzyme 
sites of EcoRV and NotI. It was named plasmid pSNAV-ASIL-5, which was following 
identified by sequencing in Shanghai Bioengineering Co. Ltd. (China). The genome 
of the recombinant pSNAV-ASIL-5 contained inverted terminal repeats of rAAV and 
CMV promoter and enhancer followed by anti-sense IL-5 cDNA and SV40 polyA. 
Plasmid pSNAV-EGFP was constructed as the same methods. 
Preparation of rAAV-ASIL-5 and rAAV-EGFP  
BHK-21 cells (ATCC, USA) were transfected with the recombinant plasmid 
pSNAV-ASIL-5 by Lipofectamine 2000 reagent (Invitrogen, USA). After 24 hours, 
the cell lines carrying pSNAV-ASIL-5 stably were obtained through G418 selection 
(neomycin, 800μg/ml) (Gibco, USA). These cell lines were plated onto a 
15-cm-diameter dish and then incubated at 37°C in 5% CO2. When it reached 90% of 
the dish (about 8×108 cells), the cells were infected by helper virus HSV-1 (30, 31) 
which containing the necessary Rep gene and Cap gene for rAAV virus replication 
and packaging at a multiplicity of infection (MOI) of 0.1. After 48 hours, all the cells 
were removed and then a single-step gravity-flow column purification method was 
carried out (32). rAAV-EGFP (green fluorescence protein gene) was constructed and 
purified using the same methods. 
The rAAV vectors were saved at -80℃ for later animal experiment. The titer and 
purity of rAAV-ASIL-5 and rAAV-EGFP were measured by Southern-Blot with a 
 dig-labeled probe and sodium dodecyl sulfate polyacrylamide gel electropheresis 
(SDS-PAGE) respectively. The infectivity of rAAV was detected by transfection ratio 
of BHK-21 cells in vitro. 
Animals  
All animal experiments were carried out according to the guidelines of the Chinese 
Council on Animal Care and approved by Tongji Hospital (Tongji Medical College, 
Huazhong University of Science and Technology, Wuhan, China) Committees on 
Animal Experimentation. The research protocol was reviewed and approved by the 
hospital institutional review board of Tongji Hospital. Forty specific pathogen-free 
adult male Sprague-Dawley (SD) rats (aged 8-12 weeks and weighted 180-210g at the 
commencement of experimental study) were obtained from animal applying center of 
Tongji Medical College (Wuhan, Hubei Province, China). All of the animals were 
housed at room temperature with 12 hours light/dark cycles and allowed free access to 
normal rat chow and water ad libitum. The animals were randomly divided equally 
into four groups: normal control group (group N), asthmatic group (group A), 
rAAV-ASIL-5 treatment group (group T) and rAAV-EGFP negative control group 
(group C). The rat model of allergic asthma was established via the method described 
previously (33). Rats were sensitized with an subcutaneous injection of 1 ml 0.2% 
(wt/vol) OVA (Grade III, Sigma, USA) complexed with 10% (wt/vol) aluminum 
hydroxide at their footpad, neck, back, groin, and abdomen on Day 1. Futhermore, 
each animal received an intramuscular injection of 2×1010 heat-killed Bacillus 
pertussis (Beijing Institute of Biological Products, China). Two weeks after the 
sensitization, the rats inhaled 1% (wt/vol) OVA for 30 minutes in an exposure 
chamber (50 cm × 30 cm × 25 cm) to challenge their airways every other day for two 
weeks. The aerosol was generated with an ultrasonic nebulizer (Shanghai KODAK 
instrument Equipment Co. LTd. China) and was drawn into an exposure chamber 
containing awaked animals. The output of the nebulizer was 3ml/min and the medium 
particle size was about 3.2μm according to specifications by the manufacturer. 
Animals in group N received a subcutaneous injection of 1 ml normal saline and were 
 exposed to aerosolized normal saline.  
Gene delivery 
Animals in group T and group C were pretreated with rAAV-ASIL-5 and 
rAAV-EGFP 0.5ml (1×1013v.g./ml) respectively on the day before sensitizing (day 0) 
and the day before challenge (day 13) via tail vein injection. Virus vectors were 
replaced by normal saline in group N and group A.  
Collecting samples 
Twenty-four hours after the last exposure to OVA or normal saline, all rats were 
anaesthetized by the intraperitoneal injection of 60 mg/kg pentobarbital. Animals 
were sterilized with 75% ethanol, fixed on operation table, opened the thoracic cavity, 
and draw blood from heart for cell count, extracted plasma. 
After haemospasia of animal, rat right bronchus was cannulated by a tracheal 
cannula and lavaged with 3ml normal saline for bronchoalveolar lavage fluid (BALF). 
BALF was recovered by gentle manual aspiration with a syringe. At the same time, 
removed the tissues of left lung, heart, liver and left kidney to fix in 4% (wt/vol) 
paraformaldehyde for 24 hours.  
Detecting the level of IL-5 protein in plasma and BALF 
Plasma was obtained from 2ml blood which was centrifuged at 1000rpm for 10 
minutes, and then saved at -80 for ELISA detection. BALF was obtained as above 
described and saved at -80 for ELISA detection. The level of IL-5 protein in plasma 
and BALF were detected by rat IL-5 ELISA kit (Rapid-bio, USA). 
Cell count of peripheral blood and BALF 
Cell count of peripheral blood: Added 3ml RBC lysis buffer to 1ml peripheral 
blood, incubated for 5 minutes, and then centrifuged at 1000rpm for 5 minutes. Cell 
pellet was suspended with 1ml normal saline. 100μl suspension was taken to white 
cell counting plate for total cells count under microscope (Nikon, Japan). At the same 
time, peripheral blood smears were made. Stained the blood smears with 
 Wright-Giemsa solution for one minute in duplicate. Added equal buffer solution and 
continue stained for 10 minutes. Finally washed with water and dry it. A differential 
count was determined on the base of standard morphologic criteria of at least 300 
cells with immersion objective microscope (34). 
Cell count of BALF: The lavage fluid was centrifuged at 1000rpm for 5 minutes at 
4℃. The supernatant was saved at -80℃ for later detection of ELISA. The cell pellet 
was washed in normal saline and incubated in 1ml NH4Cl for 5 minutes to remove red 
cells. The cell pellet was then washed twice and resuspended in 1ml normal saline. 
Total numbers of nucleated cells in BALF were determined with a cells counting plate. 
A differential cell count was performed by cell smears stained with Wright-Giemsa in 
duplicate, and was based on standard morphologic criteria of at least 300 cells with 
immersion objective microscope (34, 35). 
Detecting the level of ECP protein in plasma and BALF 
Plasma and BALF was obtained as above described and saved at -80℃ for ELISA 
detection. The level of ECP protein in plasma and BALF were detected by rat ELISA 
kit (Rapid-bio, USA) as described above. 
HE staining of tissues 
The removed tissues of left lung, heart, liver and left kidney were fixed in 4% 
(wt/vol) paraformaldehyde for 24 hours, all these tissues were embedded in paraffin 
and cut in 5μm-thick sections. Histological changes were evaluated on sections 
stained with hematoxylin and eosin (HE). The pathological variations were observed 
under microscope. 
Statistical analysis 
All data were expressed as mean ± standard deviation and analyzed by one-way 
ANOVA and q test using SPSS 12.0. A P value less than 0.05 was considered 
statistically significant. 
 
 Results 
Effect of rAAV-ASIL-5 on expression of IL-5 protein in plasma and BALF 
As shown in Figure 1, OVA sensitization and challenge markedly increased the 
level of IL-5 protein in plasma and BALF when compared with normal rats (P<0.05 
for both，group A versus group N). Treatment with rAAV-ASIL-5 significantly 
reduced the level of IL-5 protein in plasma and BALF (P<0.05 for both, group T 
versus group A), though they were still higher than normal rats (P<0.05 for both, 
group T versus group N). In contrast, treatment with rAAV-EGFP had little effect on 
the level of IL-5 protein in plasma and BALF.  
Effect of rAAV-ASIL-5 on total white cells count and eosinophils count in 
peripheral blood 
As compared with normal rats, OVA sensitization and challenge remarkably 
increased the count of total white cells in peripheral blood of (P<0.05, group A versus 
group N) (Figure 2). Treatment with rAAV-ASIL-5 significantly reduced the count of 
total white cells in peripheral blood (P<0.05, group T versus group A), but it was 
higher than normal rats (P<0.05, group T versus group N). On the contrary, treatment 
with rAAV-EGFP had no effect on the total count of white cells in peripheral blood. 
Eosinophils, which were seen few in the blood of normal rat, were strikingly 
increased in allergic rats (P<0.05, group A versus group N) (Figure 2). The count of 
eosinophils in peripheral blood was reduced markedly with treatment of 
rAAV-ASIL-5 (P<0.05, group T versus group A), though still higher than normal rats 
(P<0.05, group T versus group N). However, treatment with rAAV-EGFP had no 
effect on the count of eosinophils in peripheral blood. 
Effect of rAAV-ASIL-5 on nucleated cells count and eosinophils count in BALF 
As compared with normal rat, OVA sensitization and challenge significantly 
increased the count of nucleated cells in BALF (P<0.05, group A versus group N) 
(Figure 2). Treatment with rAAV-ASIL-5 reduced the nucleated cells count in BALF 
outstandingly (P<0.05, group T versus group A), but it was higher than normal rats 
(P<0.05, group T versus group N). Contrarily, treatment with rAAV-EGFP had no 
 effect on the count of nucleated cells in BALF. 
Eosinophils, which were nearly absent in BALF of normal rats, were increased 
observably in allergic rats (P<0.05, group A versus group N) (Figure 3). The count of 
eosinophils in BALF was markedly reduced with treatment of rAAV-ASIL-5 (P<0.05, 
group T versus group A), though still higher than normal rats (P<0.05, group T versus 
group N). But treatment with rAAV-EGFP had no effect on the count of eosinophils in 
BALF. 
Effect of rAAV-ASIL-5 on expression of ECP protein in plasma and BALF 
Considering ECP as one of the crucial monitors of eosinophils in allergic asthma 
and other eosinophilic diseases (3), we detected the expression of ECP protein in 
blood and BALF to observe the anti-eosinophil effect of this novel rAAV-ASIL-5 
vector. OVA sensitization and challenge markedly increased the level of ECP protein 
in plasma and BALF as compared with normal rats (P<0.05 for both，group A versus 
group N) (Figure 4). Treatment with rAAV-ASIL-5 notably reduced the level of ECP 
protein in plasma and BALF (P<0.05 for both, group T versus group A), though they 
were still higher than normal rats (P<0.05 for both, group T versus group N). On the 
contrary, treatment with rAAV-EGFP had almost no effect on the level of ECP protein 
in plasma and BALF.       
Effect of rAAV-ASIL-5 on lung inflammation  
We lastly observed the effect of rAAV-ASIL-5 on lung inflammation via the lung histological 
sections under microscope (Figure 5). There was no accumulation or infiltration of eosinophils 
and few other inflammation cells in lung histological sections of normal rats. No visible 
bronchoconstriction was found either. In lung pathological sections of rat models of allergic 
asthma, severe inflammation was observed such as infiltration of eosinophils and lymphocytes, 
prolification of goblet cells, bronchial smooth muscle thickening and bronchoconstriction. With 
treatment with rAAV-ASIL-5, it showed mild inflammation, slight accumulation of eosinophils 
and lymphocytes, moderate bronchoconstriction in pathological sections of lung. However, the 
treatment of rAAV-EGFP had no effect on lung inflammation. We saw no apparent pathological 
abnormality in histological sections of heart, liver and kidney in all groups (figure not shown).  
  
 
Discussion 
Previous studies have revealed that interfere of targeting IL-5 had significant 
results in suppression of eosinophils and airway hyper-reactivity in animal models of 
allergic asthma (15-17). Moreover, the anti-IL-5 therapy has shown prevention of 
eosinophils in clinic (18-20). All these researches suggested that blocking the function 
of IL-5 in vivo maybe an important strategy for developing a novel therapeutic 
approach to treat allergic asthma and other eosinophilic diseases.  
The rAAV vector, which either integrates into the genome or remains in the nucleus 
as a stable episome, offers attractive advantages and may be one of the most 
promising gene vector for long-term therapy. In our past research, we succeeded to 
construct a rAAV vector-mediated anti-sense IL-5 gene (rAAV-ASIL-5). Furthermore, 
we founded this rAAV-ASIL-5 could efficiently suppress the expression of IL-5 
mRNA and protein in CD4+ T lymphocyte from rat models of allergic asthma in vitro 
(28). 
On this base, we constructed a novel rAAV-ASIL-5 vector to carry the rat 
anti-sense IL-5 gene for animal experiment in vivo. The results of Southern-Blot and 
SDS-PAGE showed that the novel rAAV-ASIL-5 vector had properties of high-purity 
and high-titer. And we found that the novel rAAV-ASIL-5 vector could effectively 
infect BHK-21 cells in vitro (data not shown). We transfected allergic rats with the 
novel rAAV vector through tail vein injection twice and then observed its anti-IL-5 
effect in vivo. As a result, we found that the expression of IL-5 protein in lung tissue 
and blood of rAAV-ASIL-5 pretreated rat decreased markedly when compared with 
allergic rats. It suggested that the novel rAAV-ASIL-5 vector suppressed expression of 
IL-5 protein in vivo. 
Following, we observed the further anti-IL-5 effects of the novel rAAV-ASIL-5 
vector. The counts of total white cells and eosinophils in blood and BALF were 
detected. It was found that the accumulation and infiltration of eosinophils in blood 
 and airways of rAAV-ASIL-5 pretreated rats reduced remarkably, as compared with 
allergic rats. This result was concordant with many other researches (16, 17). It 
revealed the novel rAAV-ASIL-5 significantly inhibited eosinophils accumulation and 
infiltration in lung tissue and blood mainly via suppressing IL-5 expression. 
In allergic asthma and many other eosinophilic diseases, ECP and MBP level are 
related to the activity of eosinophils and thought to reflect the severity of 
inflammation (3, 36-38). They may be used as one of the objectively adjusts and 
monitors of anti-inflammatory treatment in such diseases. Considering of these, we 
detected the expression of ECP protein in blood and BALF to observe the 
anti-eosinophil effect of the novel rAAV-ASIL-5 vector. It was found interestingly 
that the expression of ECP protein in blood and BALF were all decreased 
significantly with treatment with rAAV-ASIL-5, as compared with allergic rats. These 
findings revealed that our novel rAAV-ASIL-5 vector suppressed the accumulation 
and infiltration of eosinophils as well as the release of toxic granule proteins, such as 
ECP. It may play an important role of anti-inflammation in therapy of allergic asthma.  
Finally, we observed through histological sections that the inflammation in airways 
of rAAV-ASIL-5 vector pretreated rats relieved when compared with allergic rats. All 
these results indicated that the novel rAAV-ASIL-5 expressed stablely and 
permanently in vivo, resulting in efficiently inhibition of IL-5 expression and 
eosinophils infiltration in lung and blood, as well as the secretion of toxic granule 
proteins. It may play a potential significant anti-inflammation role in the therapy of 
allergic asthma and other eosinophilic diseases. 
Although AAV could infect many kinds of tissue cells, we found no apparent 
pathological damage to vital organs of rats in our study, such as heart, liver and 
kidney et al. It revealed that the rAAV vector had no pathological affect on vital 
organs of rats in short-term. Therefore, we concluded that the novel rAAV-ASIL-5 
vector efficiently inhibited the expression of IL-5 and suppressed the accumulation of 
eosinophils in lung and blood in vivo. 
In summary, this study showed that the delivery of rAAV-mediated anti-sense IL-5 
 cDNA had the potential of preventing inflammation in allergic rats. These findings 
suggested the feasibility of rAAV for the gene therapy of allergic asthma and other 
eosinophilic diseases. No apparent adverse affects induced by rAAV injection were 
observed during the course of our study. Nevertheless, the further persistent 
anti-inflammation effects and long-term adverse effects need to be observed. The high 
level of expression from rAAV makes it attractive for human gene therapy. However, 
more experiments are needed to study the immunological aspects and the influence of 
the over-expression of the anti-sense-IL-5 gene on diverse biological processes before 
this approach is utilized clinically in the therapy of allergic asthma and other 
eosinophilic diseases. 
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Figure Legends 
Figure 1. Level of IL-5 protein in plasma and BALF in rats of normal control group 
(group N), asthmatic group (group A), rAAV-ASIL-5 treatment group (group T) and 
rAAV-EGFP negative control group (group C). Significant differences compared with 
group N shown as *P<0.05; Significant differences compared with group A shown as 
#P<0.05; Significant differences compared with group C shown as $P<0.05. 
 
Figure 2. Total cell count and eosinophil count in peripheral blood in rats of normal 
control group (group N), asthmatic group (group A), rAAV-ASIL-5 treatment group 
(group T) and rAAV-EGFP negative control group (group C). Significant differences 
compared with group N shown as *P<0.05; Significant differences compared with 
group A shown as #P<0.05; Significant differences compared with group C shown as $ 
<0.05. 
 
Figure 3. Total cell count and eosinophil count in BALF in rats of normal control 
group (group N), asthmatic group (group A), rAAV-ASIL-5 treatment group (group T) 
and rAAV-EGFP negative control group (group C). Significant differences compared 
with group N shown as *P<0.05; Significant differences compared with group A 
shown as #P<0.05; Significant differences compared with group C shown as $P<0.05. 
 
Figure 4. Level of ECP protein in plasma and BALF in rats of normal control group 
(group N), asthmatic group (group A), rAAV-ASIL-5 treatment group (group T) and 
rAAV-EGFP negative control group (group C). Significant differences compared with 
group N shown as *P<0.05; Significant differences compared with group A shown as 
#P<0.05; Significant differences compared with group C shown as $P<0.05.  
 
Figure 5 HE stainings of lung in rats of normal control group (group N), asthmatic 
 group (group A), rAAV-ASIL-5 treatment group (group T) and rAAV-EGFP negative 
control group (group C). (HE×200) 
 












